Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of DF6002 alone and combined with nivolumab in patients with advanced solid tumors: A safety and effectiveness trial

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Spain
  • Study of Abemaciclib with Irinotecan and Temozolomide for Children and Young Adults with Relapsed or Refractory Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Spain
  • Study on the Effects of Selpercatinib in Patients Aged 12 and Older with Advanced Solid Tumors with RET Gene Alteration

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Denmark France Germany Italy Spain
  • Study for Patients with Advanced Cancer Continuing Ribociclib Treatment

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Spain
  • Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    France Spain
  • Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Czechia France Germany Hungary Spain
  • Study on the Safety and Effectiveness of MK-1200 for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy Poland Spain
  • Study of Avapritinib for Children with Solid Tumors Linked to KIT or PDGFRA Signaling

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria France Germany Italy
  • Study of TYRA-300 for Patients with Advanced Bladder Cancer and Other Solid Tumors with FGFR3 Gene Changes

    Not recruiting

    2 1 1
    Investigated Drugs:
    France Italy Spain
  • Study of Atezolizumab and Tiragolumab for Patients with Resectable Solid Tumors at Intermediate-High Risk of Recurrence

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain